Press Room

News / Nov 25, 2021

Watch Luís Portela on Procurement Leaders' Extraordinary Stories

Procurement Leaders invited our Procurement Director to explain how Hovione produced and offered sanitizing agent to the community.

In 2021, Procurement Leaders – a community that provides strategy development and peer-to-peer benchmarking for Chief Procurement Officers – decided to replace their World Procurement Awards with a one-off celebration: Extraordinary Stories. These stories, from organizations across the globe recognize how procurement has stepped up in times of strain to support business performance, protect local communities and save lives during the pandemic.

 

Luís Portela, Procurement Director at Hovione, was invited to tell Hovione’s extraordinary story through this period. In a short video he explains how we produced and supplied for free, sanitizing agents at a time where this was scarcely available and speculation drove prohibitive prices.

 

We adapted sectors of our industrial facilities to produce sanitizing agent and made it available for free to our Team Members at work and at home, as well as to healthcare and social supporting institutions. This was only possible with a team effort while we continued to produce medicines that save lives without disruptions.

 

Watch the video at Procurement Leaders.com

Learn more about our efforts in the article "Stepping up to the hand sanitizer shortage" by C&EN.

 

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026